Pharmanovia A/S: Financial statements 2020
CVR: 32287824
Source: annual report 2020, Danish Business Authority
01/04/2019 – 31/03/2020
Pharmanovia A/S (CVR 32287824) has filed annual accounts for 2020. In 2020, the company reported a gross profit of DKK 3,730,176 and a net result of DKK -13,715,317 compared with DKK -5,891,089 the year before. That is a decrease of 64.9% compared with the year before. Equity in the 2020 report amounted to DKK 17,137,826. The solvency ratio was 58.8%. The company had 12 employees in the financial year.
- Gross Profit
- DKK 3,730,176
- Profit/Loss
- DKK -13,715,317
- Equity
- DKK 17,137,826
- Total Assets
- DKK 29,159,494
- Employees
- 12
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2020 | - | 3.7 mio. | -13.7 mio. | 17.1 mio. | 12 |
| 2019 | - | 10.6 mio. | -5.9 mio. | -19.9 mio. | 12 |
| 2018 | - | 2.6 mio. | -9.2 mio. | -14 mio. | 8 |
| 2015 | - | 1.5 mio. | -2.2 mio. | -12.3 mio. | 4 |
| 2014 | - | -609 t. | -3.4 mio. | -10.2 mio. | 4 |
Official annual report
How creditworthy is Pharmanovia A/S?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2020
On June 18, 2020, the company changed its name from PHARMANOVIA A/S to Atnahs Pharma Nordics A/S.
As of February 24, 2020, Anthony Charles Playle has left the board of directors of Pharmanovia A/S.
About Pharmanovia A/S
Pharmanovia A/S is a Danish company of the type Aktieselskab based in København S, founded in 2009. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named Atnahs Pharma Nordics A/S and PHARMANOVIA A/S. The management consists of Christoph Michael Habereder. The board consists of Mohammad Muqtadir Samy (chair), Christoph Michael Habereder and Twan Johannes Anna Nouwen. The company is owned by Atnahs Pharma UK Limited. The company has 3 employees (2026). In 2026, the company reported a gross profit of EUR 11,734,813 and a net result of EUR 7,730,657 compared with DKK 3,839,334 the year before. Equity in the 2026 report amounted to EUR 15,820,601.